From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

First in human studies show activation of SC-DARIC33, a rapamycin-regulated anti-CD33 CAR T cell therapy, in patients with AML

Last Updated: Friday, August 18, 2023

Preliminary correlative analyses results from the phase I PLAT-08 trial showed expanded and concurrent anti-CD33 activity in patients with rapamycin-regulated activation of SC-DARIC33 T cells.

ASGCT Abstract
Advertisement
News & Literature Highlights
Advertisement
Advertisement